Biotechnology investing is one of the most idiosyncratic sectors in the equity market. Unlike most industries where returns are driven by continuous business execution, biotech returns are frequently determined by discrete binary events — the readout of a Phase 2 or Phase 3 clinical trial, the FDA's approval or rejection decision, the emergence of competitive data from a rival drug. Understanding the framework in which these events occur is essential to any coherent view of the sector, even for investors who own biotech through diversified ETFs rather than individual names.

The clinical trial framework

Before a new drug can be marketed in the US, it must pass through a specific sequence of clinical trials designed to demonstrate safety and efficacy.

Preclinical. Laboratory and animal studies to characterise a compound's basic biology, safety, and initial efficacy signals. Most drug candidates fail here — only a small fraction of compounds identified in preclinical work progress to human trials.

Phase 1. First-in-human studies, typically in a small number (20–100) of healthy volunteers or patients with the target disease. Primary purpose is to establish safety, tolerability, and initial dosing. Very few drug candidates fail at Phase 1 for lack of efficacy (the trials are too small to measure efficacy meaningfully), but many fail for safety issues that were not visible in animal studies.

Phase 2. Studies in a larger patient population (100–500) with the target disease, designed to establish initial efficacy and further characterise safety. Phase 2 is where the majority of drug candidates fail — either the efficacy signal is weaker than the preclinical data suggested, or safety issues emerge that make the drug uncompetitive with existing treatments.

Phase 3. Large-scale studies (often 500–3,000+ patients) designed to confirm efficacy and safety at statistical significance sufficient for regulatory approval. Phase 3 trials are expensive (often exceeding $100 million per trial) and time-consuming (2–4 years typically). Success rates at Phase 3 are higher than at Phase 2 (because compounds that reached Phase 3 already showed some efficacy in Phase 2), but failures still occur regularly.

Regulatory review. After successful Phase 3 completion, the company submits a New Drug Application (NDA) or Biologics License Application (BLA) to the FDA. Review typically takes 6–10 months. FDA can approve, request additional information (delaying by many months), or reject the application.

The probability distribution

Aggregating across therapeutic areas, published data suggests the following approximate probabilities of eventual FDA approval:

  • From Phase 1 entry: approximately 10%
  • From Phase 2 entry: approximately 25%
  • From Phase 3 entry: approximately 55%

These are averages across many disease areas. The actual probabilities vary substantially by therapeutic area (oncology drugs have lower approval rates than cardiovascular drugs; rare disease drugs have higher approval rates than common disease drugs), by drug modality (small molecule versus biologic versus cell therapy versus gene therapy), and by the specific mechanism of action being targeted.

The high failure rates at each stage explain why the value of clinical-stage biotech companies is so sensitive to individual trial readouts. A Phase 3 failure that had been considered 70% likely to succeed can destroy 50–70% of a company's market cap in a single day. A Phase 2 success that had been considered 40% likely to succeed can double the market cap in a day. The binary distribution at each inflection point produces the extraordinary short-term volatility that characterises the sector.

The public-market biotech segments

The public biotech market divides into several segments with very different risk profiles.

Large-cap biotech. Companies with multiple marketed products, established revenue bases, and pipelines that support continued growth. Examples include Amgen, Gilead, Regeneron, Vertex Pharmaceuticals, and the biotech divisions of large pharma companies. Return profiles look more like specialty pharmaceutical companies than pure biotechs — steadier, more valuation-driven, less binary.

Commercial-stage single-drug companies. Companies with a single approved product generating revenue. Examples through history have included many companies that became household names for specific drugs (Regeneron before its diversification, various rare disease specialists). Return profiles depend heavily on the specific product's competitive dynamics.

Late-stage clinical companies. Companies whose value depends on Phase 3 or NDA readouts for their lead assets. The binary-outcome risk is highest here. Individual company returns can be enormous or catastrophic based on the specific readouts.

Early-stage clinical companies. Companies with only Phase 1 or Phase 2 data. Individual company returns are essentially binary lottery tickets — high probability of significant depreciation combined with occasional outsized returns from successful trials. Portfolio construction with these names requires acceptance of the binary distribution.

The ETF option

For investors who want biotech exposure without single-stock binary risk, several ETFs provide diversified exposure. XBI (SPDR S&P Biotech ETF) is equal-weighted across a broad universe of biotech names. IBB (iShares Biotechnology ETF) is market-cap-weighted and therefore more concentrated in the largest names. Various actively-managed biotech funds provide sector exposure with security selection.

The characteristics of biotech ETFs differ substantially from single-stock exposure. Diversification across dozens of names smooths out the individual binary risk — the ETF does not fall 60% when one company's Phase 3 fails, though sector-wide sentiment can still produce meaningful moves. Historical volatility of biotech ETFs is higher than the S&P 500 but much lower than individual biotech names.

The intellectual property dimension

Biotech valuation is heavily driven by intellectual property considerations that are less prominent in other sectors. A drug's economic value is bounded by its patent protection — typically 20 years from patent filing, but with meaningful adjustments for regulatory delays. The "patent cliff" — the moment when patent protection ends and generic competition arrives — can eliminate the majority of a drug's revenue within a year or two.

For companies whose valuations depend heavily on specific drugs, the patent expiration schedule is a major driver of long-term valuation. Understanding the patent estate — filing dates, patent term extensions, method-of-use patents that may extend effective exclusivity — is essential to valuing single-drug companies.

The competition dynamics

Beyond patents, biotech competition operates through multiple channels. New drugs targeting the same disease indication compete on efficacy, safety, dosing convenience, and price. Combination therapies can extend the useful life of established drugs. Biosimilars — biologically equivalent versions of biologic drugs — compete similarly to generics for small molecules, though the barriers to biosimilar development are higher.

The specific competitive dynamics vary enormously by therapeutic area. Oncology has hundreds of drugs in development for the most common cancer types, producing intense competition. Rare disease indications may have only one or two competing programs, producing near-monopoly economics for the eventually-successful drug.

The rule to internalise

Biotech investing requires accepting a return distribution that is fundamentally different from other equity sectors. Individual names carry binary-outcome risk that can produce extraordinary returns or complete losses on discrete events. Diversified sector exposure smooths this but retains sector-wide sensitivity to the overall clinical trial success environment and to the regulatory framework. Understanding the framework in which the sector operates — the clinical trial stages, the probability distributions, the intellectual property dynamics, and the competitive structure — is essential to any coherent view, whether the exposure is through individual names or through diversified vehicles.

Educational content only. Not investment advice.